Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG MIX 70 30 PENFILL.
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG MIX 70 30 PENFILL.
NOVOLOG vs NOVOLOG MIX 70/30 PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, enhancing peripheral glucose uptake, and inhibiting hepatic glucose production.
Novolog Mix 70/30 is a biphasic insulin analog suspension containing 70% insulin aspart protamine (intermediate-acting) and 30% insulin aspart (rapid-acting). Insulin aspart binds to the insulin receptor (IR) on target cells (muscle, adipose, liver), activating tyrosine kinase signaling, which promotes glucose uptake via GLUT4 translocation, inhibits hepatic gluconeogenesis, and stimulates glycogen synthesis and lipogenesis.
Subcutaneous injection: 0.5-1 unit/kg/day divided into 3 or more doses given within 15 minutes before or after meals. Typical total daily dose range 0.5-1.5 units/kg.
Subcutaneous injection, typically 0.5–1 unit/kg/day divided into two doses: two-thirds in the morning and one-third in the evening, adjusted based on blood glucose levels.
None Documented
None Documented
Terminal elimination half-life is 1.2-1.5 hours in healthy individuals, reflecting rapid clearance. In renal impairment (e.g., eGFR <30 mL/min), half-life may be prolonged up to 2-3 hours due to reduced degradation.
Biphasic: first phase (distribution) 0.5-1 h; terminal (elimination) 5-7 h (insulin aspart component). Clinical context: covers prandial and basal needs with twice-daily dosing.
Renal excretion accounts for approximately 60-80% of insulin aspart degradation products; unchanged drug is minimally excreted. Biliary/fecal excretion is negligible (<10%).
Renal: 100% (protamine and insulin are metabolized and excreted via kidneys; no unchanged drug excreted in urine). Biliary/fecal: negligible.
Category C
Category C
Insulin Analog
Insulin Analog